Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis covers the month of April 2009. The report serves to incorporate by reference three press releases issued between March 31, 2009, and April 9, 2009, detailing clinical trial results and strategic acquisitions.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notification of corporate events rather than a financial statement.
Material Changes and Corporate Events
- Clinical Data: A press release dated March 31, 2009, announced that Plavix® Plus Aspirin was more effective than Aspirin alone in preventing major vascular events in patients with atrial fibrillation who cannot take oral anticoagulants.
- Acquisition in Mexico: On April 2, 2009, Sanofi-Aventis announced the acquisition of Laboratorios Kendrick in Mexico.
- Acquisition in Brazil: On April 9, 2009, the company announced its intention to acquire Medley in Brazil.
Guidance, Outlook, and Risks
The filing text does not contain specific financial guidance, management commentary on future outlook, or a detailed discussion of risks and contingencies beyond the implications of the announced acquisitions and clinical results.
Investor Verification Checklist
- Verify the terms and financial impact of the Laboratorios Kendrick acquisition in Mexico.
- Confirm the status, valuation, and regulatory approval requirements for the proposed Medley acquisition in Brazil.
- Review the full clinical study data regarding Plavix® Plus Aspirin efficacy in atrial fibrillation patients.
- Check subsequent filings for any updates on the completion of the announced acquisitions.